Toripalimab is a selective, recombinant, humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. This antibody binds specifically to PD-1, effectively blocking its interaction with PD-L1 and PD-L2 ligands. Through this mechanism, Toripalimab disrupts the PD-1 mediated signaling pathway, which is critical in regulating the immune system's response to cancer cells. Clinically, Toripalimab has demonstrated significant anti-tumor activity across a range of malignancies, including melanoma, lung cancer, various digestive tract tumors, hepatobiliary and pancreatic cancers, neuroendocrine tumors, nasopharyngeal carcinoma, and urothelial carcinoma. This antibody is pivotal in research focused on immunotherapy and the immune evasion strategies of tumors.
Toripalimab is a selective, recombinant, humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. This antibody binds specifically to PD-1, effectively blocking its interaction with PD-L1 and PD-L2 ligands. Through this mechanism, Toripalimab disrupts the PD-1 mediated signaling pathway, which is critical in regulating the immune system's response to cancer cells. Clinically, Toripalimab has demonstrated significant anti-tumor activity across a range of malignancies, including melanoma, lung cancer, various digestive tract tumors, hepatobiliary and pancreatic cancers, neuroendocrine tumors, nasopharyngeal carcinoma, and urothelial carcinoma. This antibody is pivotal in research focused on immunotherapy and the immune evasion strategies of tumors.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
